Title

Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog.

Authors

Meece, Jerry

Abstract

Despite the continued development of new pharmacologic agents, and the use of several existing drug therapies, almost two thirds of patients with type 2 diabetes mellitus do not reach the American Diabetes Association-targeted hemoglobin Ale level of less than 7.0%. Therefore, maintaining adequate metabolic control remains a primary concern for many clinicians and patients. It is now well recognized that in addition to defective secretion and action of insulin, other hormones also potentially play a role in the development and progression of type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone from the incretin family, which stimulates insulin secretion and plays an important role in regulating the enteroinsular axis. Incretin-based therapies are the newest class of glucose-lowering drugs for the treatment of type 2 diabetes and may help address some of the unmet needs in this therapeutic area. Liraglutide is a once-daily GLP-1 analog that has been recently approved by the European Union regulatory agency and is in late-stage review by the United States Food and Drug Administration for the treatment of type 2 diabetes. The pharmacokinetic and pharmacodynamic properties of liraglutide and mechanisms behind its protracted action, which in turn enables enhanced glycemic control, are reviewed.

Subjects

PHARMACOLOGY; DIABETES; DRUG therapy; THERAPEUTICS; HEMOGLOBINS; INSULIN

Publication

Pharmacotherapy, 2009, Vol 29, Issue 12, p33S

ISSN

0277-0008

Publication type

Academic Journal

DOI

10.1592/phco.29.pt2.33S